Skip to main content

Advertisement

Table 2 Top 10 best-selling monoclonal antibody drugs in 2018

From: Development of therapeutic antibodies for the treatment of diseases

No.DrugIndication (1st US FDA Approval Year)Company2018 Revenue (USD)
1Adalimumab
(Humira)
Rheumatoid arthritis (2002)
Psoriatic arthritis (2005)
Ankylosing spondylitis (2006)
Juvenile Idiopathic Arthitis (2008)
Psoriasis (2008)
Crohn’s disease (2010)
Ulcerative colitis (2012)
Hidradenitis suppurativa (2015)
Uveitis (2018)
AbbVie$19.9 bn
2Nivolumab
(Opdivo)
Melanoma (2015)
Non-small cell lung cancer (2015)
Renal cell carcinoma (2015)
Head and neck squamous cell (2016)
Bristol-Myers Squibb$7.6 bn
3Pembrolizumab
(Keytruda)
Melanoma (2014)
Head and neck cancer (2016)
Non-small cell lung caccer (2015)
Lymphoma (2018)
Cervical cancer (2018)
Microsatellite instability-high cancer (2018)
Merck & Co$7.2 bn
4Trastuzumab
(Herceptin)
Breast cancer (1998)
Gastric cancer (2010)
Roche$7.0 bn
5Bevacizumab
(Avastin)
Colorectal cancer (2004)
Non-small cell lung caccer (2006)
Breast ERB2 negative cancer (2008)
Renal cell carcinoma (2009)
Glioblastoma (2011)
Roche$6.8 bn
6Rituximab,
(Rituxan)
Non-Hodgkin’s lymphoma (1997)
Chronic lymphocytic leukemia (2010)
Rheumatoid arthritis (2006)
Pemphigus vulgaris (2018)
Roche$6.8 bn
7Infliximab
(Remicade)
Crohn’s Disease (1998)
Rheumatoid arthritis (1999)
Ankylosing spondylitis (2004)
Ulcerative colitis (2005)
Psoriatic arthritis (2005)
Psoriasis (2006)
Johnson & Johnson$5.9 bn
8Ustekinumab
(Stelara)
Psoriasis (2009)
Psoriatic arthritis (2013)
Crohn’s Disease (2016)
Johnson & Johnson$5.2 bn
9Eculizumab
(Soliris)
Paroxysmal nocturnal hemoglobinuria (2007)
Atypical hemolytic uremic syndrome (2011)
Generalized myasthenia gravis (2017)
Neuromyelitis optica spectrum disorder (2019)
Alexion$3.6 bn
10Omalizumab
(Xolair)
Asthma (2003)
Chronic idiopathic urticaria (2014)
Roche$3.0 bn
  1. bn, billion